Mutant epidermal growth factor receptor vIII increases cell motility and clonogenecity in a prostate cell line RWPE1.
Epidermal growth faxtor receptor (EGFR)-vIII mutant has been demonstrated to over-express as prostatic neoplasms progressed from intraepithelial changes to metastatic disease. In this study, we transfected the EGFRvIII expression vector into an immortalized normal prostate epithelium cell line RWPE-1 and established stable transfectants. The cell growth, glandular morphogenesis, cell motility, and soft-agar colony formation efficiency were then studied. The results showed that EGFR-vIII mutation increased the RWPE1 cell motility and clone formation efficiency, while it had no significant effect on the cell growth when compared to non-transfected as well as mock transfected RWPE-1 cells. Moreover, EGFR-vIII changed the RWPE1 acinar morphogenesis. Further study showed that these effects of EGFR-vIII mutation may be related to down-regulation of E-cadherin and up-regulation of beta-catenin.
He
M
M
Department of Urology, Mayo Clinic, Rochester, MN 55905 USA.
Young
C Y F
CY
D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D002448:Cell Adhesion / Q000235:genetics; D002460:Cell Line; D002465:Cell Movement / Q000235:genetics*; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D050505:Mutant Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D011467:Prostate / Q000378:metabolism*; D014162:Transfection; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism
D015820:Cadherins; D050505:Mutant Proteins; D051176:beta Catenin; C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors